Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. - Wikidata - wikimedia - TriplyDB

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

http://www.wikidata.org/entity/Q37688106

about

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Recent translational research into targeted therapy for liposarcoma.Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management.The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors.Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.Recurrent paratesticular dedifferentiated liposarcoma after contralateral radical orchiectomy.

P2860

Q37702556-6A978345-33A2-4D30-84FC-C394C77718DA Q39265801-3CBF42FC-D2AB-4AEE-94FF-85C6EE9E48D7 Q41684395-55736F5F-FE81-4CE0-8BE5-8424B086AD34 Q47711378-58742BD7-0CC8-4A1C-BAA6-DCCEF2825271 Q50068220-450B3AD1-FDFA-4F7C-B46A-5D047EB1F1FB Q50868047-F67D13A4-5132-4F30-81C3-58F113789C7C Q52603062-433B6E41-4885-4B1C-A46D-F14033325D05

P2860

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

http://www.wikidata.org/entity/Q37688106

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@en

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@nl

type

label

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@en

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@nl

prefLabel

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@en

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

@nl

P1433

Q37688106-59D5219C-654E-4C72-9E01-AC88F47CF1CC

P1476

Q37688106-030DD9FE-EA8F-4B7D-A8F4-E05655166CC0

P2093

Q37688106-0F218348-F1E7-4D9D-8EC5-F7A379D53CB0

Q37688106-19FC22B9-B4A8-4A53-90C7-CB2BFDA59E24

Q37688106-274F6269-CB69-4E48-A80C-0847A527B322

Q37688106-70503E00-E34D-455F-AFBA-F6D991980445

Q37688106-C5251C3B-7715-4588-890D-152B38790611

Q37688106-E0A6AD11-9276-4611-B97C-2B99730DFF03

P2860

Q37688106-02DC5DF0-C4FA-4704-84D9-FFD397ADC14F

Q37688106-062EA97D-7877-4CC2-86D1-0F0ED5281AA8

Q37688106-0FD01533-1C30-4C72-9DC6-18BBE6F9D955

Q37688106-10012F96-A479-4860-8F82-20B1E029589C

Q37688106-10306B3B-D798-4F42-82D6-F16B45DFB38B

Q37688106-172B6605-F2EE-462D-A079-9E00ADA0288B

Q37688106-197921A6-3735-4946-8C7F-71FB3DD22C6B

Q37688106-1B239F96-9A55-48EE-8A3E-352B363FE067

Q37688106-1C259D64-9119-4CC0-B080-AF857B31DC79

Q37688106-1E1B29D7-0636-4BE3-9453-12250710CE9D

P304

Q37688106-B758EE74-511C-4F6A-BDBA-1CFF8E05DDD6

P31

Q37688106-F9FF4A28-CB1D-4BEC-8E37-28728E59CD2B

P356

Q37688106-1AAC103D-FF1A-4E6F-8F7F-3125E7739E24

P407

Q37688106-3BDABB59-B57C-4A9B-A7DE-EA4E726DDF2E

P433

Q37688106-87985A0D-CDDB-45FD-99E0-A4E29420A3C7

P478

Q37688106-9C83091A-0445-4B28-93D3-C18B15800C74

P50

Q37688106-91FAC73A-13C8-4D9B-BDEC-EF4274A6CDDA

Q37688106-E3F5C4D8-14D6-4E7A-A779-39508F36D4D6

P577

Q37688106-40F879CE-3537-4478-A4DE-72F31A575FC4

P698

Q37688106-B5099D86-AEB1-4CDB-84FF-E93671B30076

P932

Q37688106-8E1C896E-95C6-4DA1-B804-E5C2294CEAB4

P356

ONCOTARGET.10518

P1433

P1476

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma

@en

P2093

Chilamakuri Chandra Sekhar Reddy

http://www.w3.org/2001/XMLSchema#string

Iwona Grad

http://www.w3.org/2001/XMLSchema#string

Leonardo A Meza-Zepeda

http://www.w3.org/2001/XMLSchema#string

Ola Myklebost

http://www.w3.org/2001/XMLSchema#string

Robert Hanes

http://www.w3.org/2001/XMLSchema#string

Susanne Lorenz

http://www.w3.org/2001/XMLSchema#string

P2860

Differential expression analysis for sequence count data

Cellular signaling by fibroblast growth factor receptors

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

P304

54583-54595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.10518

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Eva Wessel Stratford

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27409346

http://www.w3.org/2001/XMLSchema#string

P932

5342366

http://www.w3.org/2001/XMLSchema#string